Short Interest in Entero Therapeutics, Inc. (NASDAQ:ENTO) Drops By 67.2%

Entero Therapeutics, Inc. (NASDAQ:ENTO) saw a significant drop in short interest in August. As of August 31st, there was short interest totaling 27,700 shares, a drop of 67.2% from the August 15th total of 84,400 shares. Based on an average daily volume of 1,820,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.9% of the company’s stock are short sold. Approximately 1.9% of the company’s stock are short sold. Based on an average daily volume of 1,820,000 shares, the days-to-cover ratio is currently 0.0 days.

Entero Therapeutics Stock Performance

ENTO stock opened at $2.30 on Friday. The stock’s 50 day moving average is $1.77 and its 200-day moving average is $1.50. Entero Therapeutics has a twelve month low of $0.84 and a twelve month high of $2.95.

Entero Therapeutics (NASDAQ:ENTO) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.42) EPS for the quarter.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.